Evidence map›Paper›PMID 35229254›Full record

ReviewInternational journal of hematology2022

Bosutinib-induced lung injury: a report of two cases and literature review.

Naoki Watanabe, Tomoiku Takaku, Yutaka Tsukune, Hajime Yasuda, Tomonori Ochiai, Kohei Yamada, Hiroki Nakazawa, Saori Hotta, Takayasu Nishimaki, Haruhi Takagi and 3 more

Open access · greenAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Clinical Spectrum of Bosutinib Related Side Effects in a Patient of CML: A Case Report and Review of Literature.International journal of hematology-oncology and stem cell research · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Naoki WatanabeDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Tomoiku TakakuDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. ttakaku@juntendo.ac.jp.ORCID http://orcid.org/0000-0002-6493-6225
Yutaka TsukuneDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hajime YasudaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Tomonori OchiaiDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kohei YamadaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hiroki NakazawaDepartment of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
Saori HottaDepartment of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
Takayasu NishimakiDepartment of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
Haruhi TakagiDepartment of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
Kazuhisa TakahashiDepartment of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Juntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients with chronic myeloid leukemia (CML) has improved dramatically since the development of tyrosine kinase inhibitors (TKIs). Three second-generation TKIs, including bosutinib, are currently approved for treatment of CML, and show a faster and deeper clinical response than imatinib. Common adverse events (AEs) of bosutinib are diarrhea and hepatic toxicity; however, lung complications are rare. Here, we report two cases of bosutinib-induced severe lung injury, along with a literature review. The events of these cases occurred at early time points and severity was extremely high, requiring high-flow oxygen and steroid treatments. Compared to previously reported cases, the prevalence and severity of the damage may vary among different ethnicities. However, bosutinib-induced lung injury can cause life-threatening complications. In conclusion, patients treated with bosutinib should be monitored carefully to mitigate serious drug-induced lung injury.

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung InjuryQuinolinesAniline CompoundsHumansNitrilesProtein Kinase InhibitorsAniline CompoundsAntineoplastic AgentsbosutinibNitrilesProtein Kinase InhibitorsQuinolinesBosutinibChronic myeloid leukemiaDrug-induced lung injurySteroid pulse treatmentTyrosine kinase inhibitor

Identifiers

PMID35229254
PMCPMC8884415
OpenAlexW4214522088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.